Navigation Links
Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010
Date:10/6/2010

SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California. Lorcaserin, which Arena discovered and developed, is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

"Obesity 2010 is an excellent scientific forum to present results from our recently completed clinical study evaluating the effects of lorcaserin on appetite, energy intake and energy expenditure," stated William R. Shanahan, M.D., Arena's Senior Vice President and Chief Medical Officer. "We look forward to presenting at this event, and to lorcaserin's October 22nd PDUFA date."

The meeting schedule includes presentations of a lorcaserin mechanism of action study conducted by Drs. Eric Ravussin, Leanne Redman, Corby Martin and Steven Smith at the Pennington Biomedical Research Center in Baton Rouge, Louisiana.

Saturday, October 9, 2010

  • Oral Abstract Presentation: Lorcaserin, a Novel 5-HT2C Receptor Agonist, Causes Weight Loss Without Stimulating Energy Expenditure
  • Session Time:  4:45 p.m. - 6:15 p.m. Pacific Time (PT)

  • Sunday, October 10, 2010

  • Poster Presentation: Lorcaserin, a Selective 5-HT2C Receptor Agonist, Reduces Energy Intake and Appetite
  • Session Time: The poster will be on display from 9:30 a.m. to 1:45 p.m. PT and from 3:15 p.m. to 6:30 p.m. PT. Presenters will be available to discuss the poster from 12:30 p.m. to 1:30 p.m. PT.

  • About LorcaserinLorcaserin is a new chemical entity that is
    '/>"/>

    SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Arena and Eisai Provide Update on Lorcaserin FDA Advisory Committee Meeting
    2. Arena Pharmaceuticals to Host Conference Call and Webcast Following Lorcaserin FDA Advisory Committee Meeting
    3. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
    4. Published Data Demonstrate Arena Pharmaceuticals Lorcaserin Has Low Abuse Potential
    5. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
    6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
    7. Arena Pharmaceuticals Lorcaserin to be Featured in Multiple Presentations at Obesity 2009
    8. Arena Pharmaceuticals Reports Positive, Highly Significant BLOSSOM Trial Results for Weight Management; NDA Submission on Track for December
    9. Arena Pharmaceuticals to Host Conference Call and Webcast on Friday, September 18, 2009, to Discuss Results from the BLOSSOM Phase 3 Trial of Lorcaserin for Weight Management
    10. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
    11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... Colo. , Aug. 22, 2014  Cannabis ... in cannabis formulation-based drug development and related consulting, ... iCare,s third international medical cannabis conference taking place ... Strasbourg, France , on October 22, 2014.  ... other stakeholders, such as researchers, health professionals, and ...
    (Date:8/22/2014)... - SQI Diagnostics Inc. (TSX-V: SQD), a life ... and products for advanced microarray diagnostics, today announced ... Agreement to contract with a UK-based company to ... initial phase of this agreement, SQI will be ... one of the customer,s assays, operational on SQI,s ...
    (Date:8/21/2014)... , Aug. 21, 2014  Aptuit LLC ... West Lafayette, Indiana , has enhanced its ... characterization of small and large molecules, including biologic ... the Bruker maXisPlus Q-TOF mass spectrometer. ... , CEO, Aptuit, said, "The expanded large molecule ...
    Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2
    ... SYDNEY, May 23, 2011 Starpharma Holdings Limited (ASX: ... major phase 2 clinical study that demonstrated efficacy of ... Key Points: VivaGel(R) ... BV VivaGel(R) expected to avoid many shortcomings of ...
    ... Mass., May 20, 2011 Philips ... Philips FilterLine H Set and VitaLine H Set ... November 2010 through March 2011.ProductProduct DescriptionProduct Lot CodesM1923A ... M8330M10M8386N10M8411P10M8451P10M8477A11M8514A11M8572B11989803159581 , Philips Vitaline H Set Infant/Neo ...
    Cached Medicine Technology:VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 2VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 3VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 4VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis 5Recall of Infant and Neonatal-Sized FilterLine H Set and VitaLine H Set Sampling Lines 2
    (Date:8/22/2014)... FL (PRWEB) August 22, 2014 ... treatment facility in Lantana, FL, recently launched a ... just looking for information can now find Millennium ... new website just went live at the beginning ... about the facility can be found on the ...
    (Date:8/22/2014)... Beat Eczema , Susan Clark’s ... natural methods to completely cure the eczema symptoms they ... Shane Michaels, prompting an investigative review. , “Although ... it can still be extremely debilitating and life-altering for ... itching and pain that it causes on the skin ...
    (Date:8/22/2014)... in advanced non-small cell lung cancer (NSCLC) is ... epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ... deletion independently predicts overall survival (OS) of advanced ... the programmed cell death also known as the ... detected in 12.8% of the Asian population but ...
    (Date:8/22/2014)... receptor (EGFR) mutations found in the circulating free tumor ... lung cancer (NSCLC) patients correlates well with the EGFR ... kinase inhibitor (TKI) therapy is approved for EGFR activating ... for determining mutation status is with DNA derived directly ... available. A more abundant and less invasive source of ...
    (Date:8/22/2014)... August 22, 2014 Paying tuition and ... in the coming year for four nurse educators pursuing ... National League for Nursing Foundation for Nursing Education . ... share $28,000, $10,000 more than in 2013, thanks to ... Endowment and Elizabeth Isaac Marcil Endowment Funds, both donated ...
    Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Has a New Website 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3
    ... has been aroused in the identification and isolation of ... of bone marrow cells have been found to have ... on immunological methods is difficult because of the complicated ... of successful passage has been published., A research article ...
    ... , , WEDNESDAY, April 15 (HealthDay News) -- If you have ... or pop in a CD of mellow songs. , Hospital ... rate and blood pressure just by listening to music, a ... report, published in the latest issue of The Cochrane ...
    ... Delcath Systems, Inc. (Nasdaq: DCTH ) ... PM Eastern Time on Wednesday, April 22, 2009. Richard ... will host the call.(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ... parties may dial (888) 790-3326 (U.S./Canada) and use Conference ...
    ... MOUNTAIN VIEW, Calif., April 15 Based on ... tomography (PET) and PET/computed tomography (CT) markets market, ... the 2009 North American Frost & Sullivan Award ... forth innovative scintillation crystal and solid-state photo detector ...
    ... CITRUS HEIGHTS, Calif., April 15 In response ... (EHR) for all patients, SMART Association, Inc. and ... their LifeMed(TM) Smart Card Platform software for EHRs. ... ("HIEs"), hospital legacy systems, or physicians, record management ...
    ... need to evaluate options for continuing healthcare coverage , ... ... the 2009 American Recovery and Reinvestment Act (ARRA) may be crucial ... people with disabilities no longer able to work, according to ...
    Cached Medicine News:Health News:Soothing Songs Please the Heart 2Health News:Delcath Systems to Host Quarterly Update Conference Call 2Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 2Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 3Health News:Frost & Sullivan Recognizes Zecotek Photonic's Medical Imaging Achievement, Development of Next-Generation Scintillation Crystals and Photo Detector Technology 4Health News:SMART Association, Inc. Launches Its Health Information Exchange Software 2Health News:SMART Association, Inc. Launches Its Health Information Exchange Software 3Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 2Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 3Health News:Jobless Should Evaluate COBRA, Medicare in Light of 2009 Recovery Act 4
    Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Round handle manufactured in titanium....
    Utrata-like fine angled tips with gently curved shaft for performing capsulorhexis through tunnel incisions. Dull finish. Flat handle....
    McPherson handle. 45 degree angled shafts. Manufactured in titanium....
    This cross action forcep has delicate tips for grasping the capsule. The forcep has an iris stop to prevent inadvertent grasping of the iris....
    Medicine Products: